The pharmacokinetics of ropivacaine in hepatic and renal insufficiency

• Published in: Best practice & research. Clinical anaesthesiology Vol. 19; no. 2; pp. 269 - 274
• Main Author: Jokinen, Mika J.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01-06-2005; The Lancet Publishing Group, a division of Elsevier Science Ltd
• Subjects: Amides - pharmacokinetics; Anesthetics; Anesthetics, Local - pharmacokinetics; Animals; Care and treatment; Humans; Kidney diseases; liver diseases; Liver Diseases - metabolism; Pharmacokinetics; Renal Insufficiency - metabolism; ropivacaine; United States; ropivacaine; pharmacokinetics; liver diseases; kidney diseases
• ISSN: 1521-6896; 1532-169X
• DOI: 10.1016/j.bpa.2004.12.002

In patients with chronic end-stage liver disease, the peak plasma concentrations of ropivacaine after a single intravenous ropivacaine dose are similar to those in healthy subjects. However, patients with end-stage liver disease have about a 60% lower mean ropivacaine clearance than healthy subjects and are thus expected to have over two-fold higher steady-state ropivacaine plasma concentrations during a continuous ropivacaine infusion. The peak plasma concentrations of ropivacaine after an axillary plexus block in uraemic patients are considerably higher than those in non-uraemic patients. However, uraemic patients have significantly higher alpha-1-acid glycoprotein plasma concentrations than non-uraemic patients, and the peak plasma concentrations of free ropivacaine (related to toxicity) are similar in both groups. The pharmacokinetics of intravenously administered ropivacaine in patients with renal insufficiency and the possibility of clinically significant (
S)-2′,6′-pipecoloxylidide metabolite accumulation during continuous or repeated ropivacaine administration in these patients remain to be clarified.